Everyone at least on the board is in ARRY for the MEK inhibitior, glucose kinase activator, and 614. If the run-up was because some fund managers recognizing the potential of ARRY, you would expect today to be a shopping opportunity. Down 15% just doesn't make any sense to me unless the run-up was for 797.
Market Data 
Markets 
AI
